

Heard 10/625,103

=> D HIS

(FILE 'CAPLUS' ENTERED AT 14:42:15 ON 15 NOV 2004)  
DEL HIS Y

FILE 'REGISTRY' ENTERED AT 14:42:43 ON 15 NOV 2004  
ACT HEARD625/A

-----  
L1 STR  
L2 1591 SEA FILE=REGISTRY SSS FUL L1  
-----  
ACT HEARDSEQ/A  
-----  
L3 28 SEA FILE=REGISTRY ABB=ON PLU=ON WQEWEQKITALLEQAQIQQEKNYEYLQKL  
L4 1 S 251562-00-2  
SET SMARTSELECT ON  
L5 SEL L3 1- RN : 28 TERMS  
SET SMARTSELECT OFF  
L6 0 S L5/CRN  
L7 0 S 251562-00-2/CRN  
-----  
FILE 'CAPLUS' ENTERED AT 14:43:41 ON 15 NOV 2004  
L8 515 S L2  
L9 45 S L3 OR L4  
L10 1 S L8 AND L9  
L11 42 S T1249 OR T 1249 OR T1249/AB OR T 1249/AB  
L12 1 S L11 AND L2  
L13 1 S L10 OR L12

Heard 10/625,103

=> fil reg  
FILE 'REGISTRY' ENTERED AT 14:45:13 ON 15 NOV 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 NOV 2004 HIGHEST RN 780728-63-4  
DICTIONARY FILE UPDATES: 14 NOV 2004 HIGHEST RN 780728-63-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d que stat 12  
L1 STR  
13  
O  
||  
CH2-CH2-O---G1---C-----NH-G2---CH2  
4 5 6 7 8 10 11 12

REP G1=(1-17) CH2  
REP G2=(1-3) CH2  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE  
L2 1591 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 213472 ITERATIONS 1591 ANSWERS  
SEARCH TIME: 00.00.04

=> d que 13  
L3 28 SEA FILE=REGISTRY ABB=ON PLU=ON WQEWEQKITALLEQAQIQQEKENYEYLQKL  
DKWASLWEWF/SQSP

See for T 1249

=> d que 14;d 14  
L4 1 SEA FILE=REGISTRY ABB=ON PLU=ON 251562-00-2

Heard 10/625,103

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 251562-00-2 REGISTRY  
CN L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutaminyl-L- $\alpha$ -glutamyl-L-tryptophyl-L- $\alpha$ -glutamyl-L-glutaminyl-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L- $\alpha$ -glutamyl-L-glutaminyl-L-alanyl-L-glutaminyl-L-isoleucyl-L-glutaminyl-L-lysyl-L-asparaginyl-L- $\alpha$ -glutamyl-L-tyrosyl-L- $\alpha$ -glutamyl-L-leucyl-L-glutaminyl-L-lysyl-L-leucyl-L- $\alpha$ -aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L- $\alpha$ -glutamyl-L-tryptophyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1: PN: WO9959615 PAGE: 68 claimed protein

CN T 1249

CN Tifuvirtide

FS PROTEIN SEQUENCE

MF C235 H341 N57 O67

CI MAN

SR CA

LC STN Files: BIOSIS, BIOTECHNO, CA, CAPLUS, EMBASE, IMSRESEARCH, PHAR, PROUSDDR, TOXCENTER, USPAT2, USPATFULL

DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

30 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

32 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d que 16

L3 28 SEA FILE=REGISTRY ABB=ON PLU=ON WQEWEQKITALLEQAQIQQEKNEYELQKL  
DKWASLWEWF/SQSP

L5 SEL PLU=ON L3 1- RN : 28 TERMS

L6 0 SEA FILE=REGISTRY ABB=ON PLU=ON L5/CRN

=> d que 17

L7 0 SEA FILE=REGISTRY ABB=ON PLU=ON 251562-00-2/CRN

=> fil caplus

FILE 'CAPLUS' ENTERED AT 14:45:41 ON 15 NOV 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

Heard 10/625,103

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Nov 2004 VOL 141 ISS 21  
FILE LAST UPDATED: 14 Nov 2004 (20041114/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d que nos 113

L1	STR
L2	1591 SEA FILE=REGISTRY SSS FUL L1
L3	28 SEA FILE=REGISTRY ABB=ON PLU=ON WQEWEQKITALLEQAQIQQEKENYELQKL DKWASLWEWF/SQSP
L4	1 SEA FILE=REGISTRY ABB=ON PLU=ON 251562-00-2
L8	515 SEA FILE=CAPLUS ABB=ON PLU=ON L2
L9	45 SEA FILE=CAPLUS ABB=ON PLU=ON L3 OR L4
L10	1 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND L9
L11	42 SEA FILE=CAPLUS ABB=ON PLU=ON T1249/OBI OR T 1249/OBI OR T1249/AB OR T 1249/AB
L12	1 SEA FILE=CAPLUS ABB=ON PLU=ON L11 AND L2
L13	1 SEA FILE=CAPLUS ABB=ON PLU=ON L10 OR L12

=> d .ca hitstr l13 1

L13	ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:	2004:120875 CAPLUS
DOCUMENT NUMBER:	140:187355
TITLE:	Preparation of PEGylated T1249 polypeptide conjugates as antiviral agents
INVENTOR(S):	Bailon, Pascal Sebastian; Won, Chee-Youb
PATENT ASSIGNEE(S):	F. Hoffmann-La Roche AG, Switz.
SOURCE:	PCT Int. Appl., 61 pp.
CODEN:	PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004013165	A1	20040212	WO 2003-EP7711	20030716
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

Heard 10/625,103

US 2004171542 PRIORITY APPLN. INFO.:	A1 20040902	US 2003-625103 US 2002-398190P US 2003-439213P	20030722 P 20020724 P 20030110
---	-------------	--	--------------------------------------

AB PEGylated T1249 polypeptide compds. are provided. Also provided are pharmaceutical compns. containing pegylated T1249 polypeptide compds., and processes of making. Further provided is the use of pharmaceutical composition comprising, in admixt. with a pharmaceutically acceptable excipient, a PEGylated T1249 polypeptide conjugate, for the preparation of a medicament for the inhibition of HIV infection. Propionaldehyde-PEG was reacted with T1249 to obtain propionaldehyde-PEG-T1249 conjugate. Antiviral efficacy of the conjugate was shown in rats.

IC ICM C07K014-16  
ICS A61K038-16; A61P031-18

CC 63-5 (Pharmaceuticals)  
Section cross-reference(s): 1

ST PEGylated T1249 polypeptide conjugates antiviral

IT Drug delivery systems  
(freeze-dried; preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)

IT Drug delivery systems  
(infusions; preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)

IT Drug delivery systems  
(injections, i.m.; preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)

IT Drug delivery systems  
(injections, i.p.; preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)

IT Drug delivery systems  
(injections, i.v.; preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)

IT Drug delivery systems  
(injections, s.c.; preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)

IT Drug delivery systems  
(injections; preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)

IT Bioavailability  
Human immunodeficiency virus  
(preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)


IT 125061-88-3DP, reaction with T1249 251562-00-2DP,  
T1249, conjugates with polyethylene glycol derivs.  
650634-82-5DP, reaction with T1249 650634-82-5P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)

IT 5292-43-3, tert-Butyl bromoacetate 6346-09-4, 4-Aminobutyraldehyde diethylacetal 9004-74-4, Methoxypolyethylene glycol 125061-88-3 251562-00-2, T1249  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)


IT 67665-18-3P 650634-81-4P 656807-59-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of PEGylated T1249 polypeptide conjugates as

Heard 10/625, 103

- IT antiviral agents)  
IT 658963-49-6  
RL: PRP (Properties)  
(unclaimed protein sequence; preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)  
IT 251651-38-4 658681-54-0 658681-55-1 658681-56-2  
RL: PRP (Properties)  
(unclaimed sequence; preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)  
IT 251562-00-2DP, T1249, conjugates with polyethylene glycol derivs. 650634-82-5DP, reaction with T1249  
650634-82-5P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)  
RN 251562-00-2 CAPLUS  
CN L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutaminyl-L- $\alpha$ -glutamyl-L-tryptophyl-L- $\alpha$ -glutamyl-L-glutaminyl-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L- $\alpha$ -glutamyl-L-glutaminyl-L-alanyl-L-glutaminyl-L-isoleucyl-L-glutaminyl-L-glutaminyl-L- $\alpha$ -glutamyl-L-lysyl-L-asparaginyl-L- $\alpha$ -glutamyl-L-tyrosyl-L- $\alpha$ -glutamyl-L-leucyl-L-glutaminyl-L-lysyl-L-leucyl-L- $\alpha$ -aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L- $\alpha$ -glutamyl-L-tryptophyl- (9CI) (CA INDEX NAME)  
  
\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
RN 650634-82-5 CAPLUS  
CN Poly(oxy-1,2-ethanediyl),  $\alpha$ -methyl- $\omega$ -[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)



- RN 650634-82-5 CAPLUS  
CN Poly(oxy-1,2-ethanediyl),  $\alpha$ -methyl- $\omega$ -[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)



- IT 251562-00-2, T1249  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)  
RN 251562-00-2 CAPLUS  
CN L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutaminyl-L- $\alpha$ -glutamyl-L-tryptophyl-L- $\alpha$ -glutamyl-L-glutaminyl-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L- $\alpha$ -glutamyl-L-glutaminyl-L-alanyl-L-glutaminyl-L-isoleucyl-L-glutaminyl-L-glutaminyl-L- $\alpha$ -glutamyl-L-lysyl-L-asparaginyl-L- $\alpha$ -glutamyl-L-tyrosyl-L- $\alpha$ -

Heard 10/625, 103

glutamyl-L-leucyl-L-glutaminyl-L-lysyl-L-leucyl-L- $\alpha$ -aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L- $\alpha$ -glutamyl-L-tryptophyl- (9CI) (CA INDEX NAME)


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 650634-81-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)

RN 650634-81-4 CAPLUS

CN Poly(oxy-1,2-ethanediyl),  $\alpha$ -[2-[(4,4-diethoxybutyl)amino]-2-oxoethyl]- $\omega$ -methoxy- (9CI) (CA INDEX NAME)



IT 658963-49-6

RL: PRP (Properties)

(unclaimed protein sequence; preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)

RN 658963-49-6 CAPLUS

CN L-Phenylalanine, L-tryptophyl-L-glutaminyl-L- $\alpha$ -glutamyl-L-tryptophyl-L- $\alpha$ -glutamyl-L-glutaminyl-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L- $\alpha$ -glutamyl-L-glutaminyl-L-alanyl-L-glutaminyl-L-isoleucyl-L-glutaminyl-L-glutaminyl-L- $\alpha$ -glutamyl-L-lysyl-L-asparaginyl-L- $\alpha$ -glutamyl-L-tyrosyl-L- $\alpha$ -glutamyl-L-leucyl-L-glutaminyl-L-lysyl-L-leucyl-L- $\alpha$ -aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L- $\alpha$ -glutamyl-L-tryptophyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

=>